← Leaderboards
Anumantha Gounder Kanthasamy
University Of Georgia
$28,784,345
Attributed
$39,252,303
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,252,303 · 18
By mechanism
R01$26,677,795 · 13
U01$11,412,524 · 2
R33$765,114 · 1
R61$386,870 · 1
R13$10,000 · 1
Top collaborators
- Arthi Kanthasamy9 shared
- Xuemei Huang7 shared
- Balaraman Kalyanaraman5 shared
- Charles H Adler4 shared
- Thomas G Beach4 shared
- Gregory J Phillips4 shared
- Richard B Mailman1 shared
Most similar at University Of Georgia
Same institution · by research overlap
- Arthi Kanthasamy$7,127,865
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsNerve DegenerationMolecularAnimal ModelNeurodegenerative DisordersBrainChronicOxidative StressMouse ModelSignal TransductionParkinson DiseaseMitochondriaNeurochemistryCellsResponseCell Culture TechniquesNeurotoxicityProteinsMediatingInsightApoptosisExposure ToApoptoticParkinsonian Disorders
Grant awards (93)
Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer's Disease and Related Dementias$1,441,664
U01 · FY2025 · AG · contact PI
Novel Epitranscriptomic Mechanisms in Metal Neurotoxicity$441,529
R01 · FY2025 · ES · contact PI
Compensatory Mitochondrial Protective Mechanisms Against Oxidative Stress in PD$436,013
R01 · FY2025 · NS · contact PI
Role of Prokineticin 2 in Metal Neurotoxicity$339,750
R01 · FY2025 · ES · contact PI
Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer's Disease and Related Dementias$1,492,444
U01 · FY2024 · AG · contact PI
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias$571,411
R01 · FY2024 · NS
Compensatory Mitochondrial Protective Mechanisms Against Oxidative Stress in PD$422,932
R01 · FY2024 · NS · contact PI
Role of Prokineticin 2 in Metal Neurotoxicity$339,750
R01 · FY2024 · ES · contact PI
Role of Prokineticin 2 in Metal Neurotoxicity$331,166
R01 · FY2024 · ES · contact PI
Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer's Disease and Related Dementias$1,503,532
U01 · FY2023 · AG · contact PI
Discovery of Multimodal Biomarkers for Parkinsonian Syndromes, Their Progression, and Pathological Relevance$742,806
U01 · FY2023 · NS
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias$569,916
R01 · FY2023 · NS
Compensatory Mitochondrial Protective Mechanisms Against Oxidative Stress in PD$436,013
R01 · FY2023 · NS · contact PI
Novel Re-engineered L DOPA Probiotic Therapy for Parkinson's Disease$364,657
R33 · FY2023 · NS · contact PI
Role of Prokineticin 2 in Metal Neurotoxicity$339,750
R01 · FY2023 · ES · contact PI
Discovery of Multimodal Biomarkers for Parkinsonian Syndromes, Their Progression, and Pathological Relevance$1,548,629
U01 · FY2022 · NS
Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer's Disease and Related Dementias$1,459,176
U01 · FY2022 · AG · contact PI
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias$572,495
R01 · FY2022 · NS
Compensatory Mitochondrial Protective Mechanisms Against Oxidative Stress in PD$436,013
R01 · FY2022 · NS · contact PI
Novel Re-engineered L DOPA Probiotic Therapy for Parkinson's Disease$400,457
R33 · FY2022 · NS · contact PI
Discovery of Multimodal Biomarkers for Parkinsonian Syndromes, Their Progression, and Pathological Relevance$805,823
U01 · FY2021 · NS
Discovery of Multimodal Biomarkers for Parkinsonian Syndromes, Their Progression, and Pathological Relevance$745,565
U01 · FY2021 · NS
Blinded Comparison of Different Alpha-Synuclein Seeding Assays as Cutaneous Biomarkers of Lewy Body Dementias$621,264
R01 · FY2021 · NS
Neuroinflammation and microglial Kv1.3 in Parkinsons disease$373,549
R01 · FY2021 · NS · contact PI
Novel Mechanisms of Pesticide-Induced Neurotoxicity$192,946
R01 · FY2021 · ES · contact PI
Novel Mechanisms of Pesticide-Induced Neurotoxicity$145,991
R01 · FY2021 · ES · contact PI
Discovery of Multimodal Biomarkers for Parkinsonian Syndromes, Their Progression, and Pathological Relevance$142,746
U01 · FY2021 · NS
Discovery of Multimodal Biomarkers for Parkinsonian Syndromes, Their Progression, and Pathological Relevance$757,369
U01 · FY2020 · NS
Neuroinflammation and microglial Kv1.3 in Parkinsons disease$374,268
R01 · FY2020 · NS · contact PI
Novel Mechanisms of Pesticide-Induced Neurotoxicity$333,663
R01 · FY2020 · ES · contact PI
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity.$329,840
R01 · FY2020 · ES · contact PI
Novel Re-engineered L DOPA probiotic therapy for Parkinsons Disease$224,584
R61 · FY2020 · NS · contact PI
Novel Re-engineered L DOPA probiotic therapy for Parkinsons Disease$162,286
R61 · FY2020 · NS · contact PI
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity$1
R01 · FY2020 · ES · contact PI
Discovery of Multimodal Biomarkers for Parkinsonian Syndromes, Their Progression, and Pathological Relevance$772,770
U01 · FY2019 · NS
Neuroinflammation and microglial Kv1.3 in Parkinsons disease$374,658
R01 · FY2019 · NS · contact PI
Novel Mechanisms of Pesticide-Induced Neurotoxicity$334,090
R01 · FY2019 · ES · contact PI
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity$328,176
R01 · FY2019 · ES · contact PI
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity$382,500
R01 · FY2018 · ES · contact PI
Neuroinflammation and microglial Kv1.3 in Parkinsons disease$374,658
R01 · FY2018 · NS · contact PI
Novel Mechanisms of Pesticide-Induced Neurotoxicity$333,984
R01 · FY2018 · ES · contact PI
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity$328,552
R01 · FY2018 · ES · contact PI
Neuroinflammation and microglial Kv1.3 in Parkinsons disease$385,584
R01 · FY2017 · NS · contact PI
Novel Mechanisms of Pesticide-Induced Neurotoxicity$332,819
R01 · FY2017 · ES · contact PI
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity$328,912
R01 · FY2017 · ES · contact PI
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity$329,259
R01 · FY2016 · ES · contact PI
Mechanisms of Manganese Neurotoxicity$321,873
R01 · FY2015 · ES · contact PI
Oxidative Stress Induced Compensatory Protective Mechanisms in PD$319,055
R01 · FY2015 · NS · contact PI
Role of Prion Protein in Manganese Neurotoxicity$321,828
R01 · FY2014 · ES · contact PI
Mechanisms of Manganese Neurotoxicity$319,098
R01 · FY2014 · ES · contact PI
Oxidative Stress Induced Compensatory Protective Mechanisms in PD$316,052
R01 · FY2014 · NS · contact PI
Role of Prion Protein in Manganese Neurotoxicity$48,871
R01 · FY2014 · ES · contact PI
Role of Prion Protein in Manganese Neurotoxicity$672,690
R01 · FY2013 · ES · contact PI
Neuroprotection by Mitochondria-targeted Antioxidants$510,053
R01 · FY2013 · NS
Mechanisms of Manganese Neurotoxicity$316,296
R01 · FY2013 · ES · contact PI
Oxidative Stress Induced Compensatory Protective Mechanisms in PD$308,246
R01 · FY2013 · NS · contact PI
Role of Prion Protein in Manganese Neurotoxicity$686,857
R01 · FY2012 · ES · contact PI
Neuroprotection by Mitochondria-targeted Antioxidants$526,381
R01 · FY2012 · NS
Role of Prion Protein in Manganese Neurotoxicity$374,193
R01 · FY2012 · ES · contact PI
Mechanisms of Manganese Neurotoxicity$323,165
R01 · FY2012 · ES · contact PI
Oxidative Stress Induced Compensatory Protective Mechanisms in PD$319,600
R01 · FY2012 · NS · contact PI
Neuroprotection by Mitochondria-targeted Antioxidants$536,010
R01 · FY2011 · NS
Role of Prion Protein in Manganese Neurotoxicity$325,079
R01 · FY2011 · ES · contact PI
Mechanisms of Manganese Neurotoxicity$323,561
R01 · FY2011 · ES · contact PI
Oxidative Stress Induced Compensatory Protective Mechanisms in PD$319,767
R01 · FY2011 · NS · contact PI
Neuroprotection by Mitochondria-targeted Antioxidants$557,341
R01 · FY2010 · NS
Role of Prion Protein in Manganese Neurotoxicity$328,362
R01 · FY2010 · ES · contact PI
Mechanisms of Manganese Neurotoxicity$301,432
R01 · FY2010 · ES · contact PI
Mechanisms of Manganese Neurotoxicity$29,900
R01 · FY2010 · ES · contact PI
Neuroprotection by Mitochondria-targeted Antioxidants$509,641
R01 · FY2009 · NS
Mechanisms of Manganese Neurotoxicity$294,181
R01 · FY2009 · ES · contact PI
NEUROPROTECTIVE STRATEGIES AGAINST OXIDATIVE DAMAGE$285,208
R01 · FY2009 · NS · contact PI
Mechanisms of Manganese Neurotoxicity$294,381
R01 · FY2008 · ES · contact PI
NEUROPROTECTIVE STRATEGIES AGAINST OXIDATIVE DAMAGE$253,609
R01 · FY2008 · NS · contact PI
Mechanisms of Manganese Neurotoxicity$323,646
R01 · FY2007 · ES · contact PI
NEUROPROTECTIVE STRATEGIES AGAINST OXIDATIVE DAMAGE$254,237
R01 · FY2007 · NS · contact PI
Mechanisms of Manganese Neurotoxicity$310,612
R01 · FY2006 · ES · contact PI
CASPASES, MITOCHONDRIAL FUNCTION AND PARKINSON'S DISEASE$304,741
R01 · FY2006 · NS · contact PI
NEUROPROTECTIVE STRATEGIES AGAINST OXIDATIVE DAMAGE$286,472
R01 · FY2006 · NS · contact PI
CASPASES, MITOCHONDRIAL FUNCTION AND PARKINSON'S DISEASE$312,075
R01 · FY2005 · NS
NEUROPROTECTIVE STRATEGIES AGAINST OXIDATIVE DAMAGE$270,740
R01 · FY2005 · NS
CASPASES, MITOCHONDRIAL FUNCTION AND PARKINSON'S DISEASE$335,250
R01 · FY2004 · NS
MMT, DOPAMINERGIC DEGENERATION, AND AGING$289,000
R01 · FY2004 · ES
CASPASES, MITOCHONDRIAL FUNCTION AND PARKINSON'S DISEASE$312,075
R01 · FY2003 · NS
NEUROPROTECTIVE STRATEGIES IN PARKINSONS DISEASE$290,489
R01 · FY2003 · NS
MMT, DOPAMINERGIC DEGENERATION, AND AGING$289,000
R01 · FY2003 · ES
MMT, DOPAMINERGIC DEGENERATION, AND AGING$289,000
R01 · FY2002 · ES
NEUROPROTECTIVE STRATEGIES IN PARKINSONS DISEASE$248,241
R01 · FY2002 · NS
MMT, DOPAMINERGIC DEGENERATION, AND AGING$314,000
R01 · FY2001 · ES
NEUROPROTECTIVE STRATEGIES IN PARKINSONS DISEASE$241,023
R01 · FY2001 · NS
MMT, DOPAMINERGIC DEGENERATION, AND AGING$289,000
R01 · FY2000 · ES
NEUROPROTECTIVE STRATEGIES IN PARKINSONS DISEASE$234,012
R01 · FY2000 · NS
3RD INT CONF ON FREE RADICALS IN HEALTH &DISEASE$10,000
R13 · FY2000 · AG